Population Level Screening to Detect Early Stage Type 1 Diabetes
Diabetes Insights - Breakthroughs and InnovatorsShow Notes
In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes.
They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers.
From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in type 1 diabetes care in decades.
More from Diabetes Insights - Breakthroughs and Innovators
In this EASD TV interview, Prof. Zachary Gerhart-Hines (Novo Nordisk Foundation Center for Basic Metabolic Research), 61st EASD Minkowski Prize recipient, discusses research into the neurokinin-2 receptor (NK2R) and its potential to change how we approach weight management and metabolic health. Where many existing treatments focus on reducing food intake, NK2R activation could offer a complementary strategy by increasing energy expenditure, influencing appetite and improving insulin sensitivity.
How does exercise stimulate glucose uptake in muscle and what can this teach us about treating type 2 diabetes?
Prof. Anette-Gabriele Ziegler, this year’s Claude Bernard Prize Lecture recipient, reflects on her career in type 1 diabetes research and the evolution of our understanding of the disease.
The EASD’s first clinical practice guideline on the assessment and management of diabetes distress in adults living with type 1 or type 2 diabetes has now been published in Diabetologia.
How can people living with diabetes help shape the future of diabetes care?